THE ROLE OF PATENT BLUE V IN REVERSE AXILLARY MAPPING IN PATIENTS UNDERGOING SENTINEL AXILLARY LYMPH NODE BIOPSY FOR BREAST CANCER -INITIAL RESULTS
Purpose:The main purpose of this study is to research the initial experience with Patent Blue V as a tracer for reverse axillary mapping during sentinel lymph node biopsy for breast cancer and look into the lymphedema rates. Methods:We analyzed the first consecutive patients who underwent senti...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Trakia University
2024-09-01
|
| Series: | Trakia Journal of Sciences |
| Subjects: | |
| Online Access: | https://tjs.trakia-uni.bg/index.php/tjs/article/view/45/48 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose:The main purpose of this study is to research the initial experience with Patent Blue V as a tracer for reverse axillary mapping during sentinel lymph node biopsy for breast cancer and look into the lymphedema rates. Methods:We analyzed the first consecutive patients who underwent sentinel axillary lymph node dissectionwith ICGin combination with reverse axillary mapping with Patent Blue V for the period from May 2023 to January 2024 at our clinic. Results:Thirteen patients were included. Patent Blue V (reverse axillary mapping tracer)was found intraoperatively in only two patients (15%). ICG (sentinel lymph nodebiopsy tracer) was found in 100% of the patients. No lymphedema of upper limb was found with a mean follow-up of 4.2 months.Conclusions:The use of Patent BlueVseemsnotto beanefficientmethodfor reverse axillary mapping with a success rate of 15% in this study. The use of another tracker for reverse axillary mappingis appropriate. However, no upper extremity lymphedema is reported in patients after sentinel lymph node biopsy in this study. |
|---|---|
| ISSN: | 1313-3551 |